A Study to Evaluate the Long-Term Safety of CLBR001, A Lentiviral Based Chimeric Antigen Receptor, In Patients With B-Cell Malignancies Previously Administered CLBR001

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 20 Mar 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs CLBR 001-SWI 019-Abbvie/California Institute for Biomedical Research (Primary)
Indications B-cell lymphoma
Focus Adverse reactions

11 Dec 2020 Planned End Date changed from 1 Aug 2038 to 1 Aug 2036.
11 Dec 2020 Planned primary completion date changed from 1 Aug 2038 to 1 Aug 2036.
11 Dec 2020 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com